On the launch pad...Merger closed.
Board of Directors approved.
New company name approved.
New stock symbol, branding, and website incoming.
1) Diagnostic: Last patient last visit for the pediatric diagnostic trial 35 days ago. Adult top-line results were reported 36 days after the trial was completed. Full results expected this quarter. Licensing deal was anticipated based on outreach last July. A licensing deal was previuosly signed one month after FDA regulatory approval.
2) Avenanthramide pill: 49 days since "shortly":
"Based on full report to be completed shortly, members of the Data Safety Monitoring Board will decide on conducting the next step of the Phase 1 study consisting of three additional groups of 8 subjects per group where each subject will receive multiple ascending dose (MAD)."
3) PGX-Fibrosis: It's been 80 days since a comprehensive article was said "recently" submitted to Biomaterials. On average it takes 131 days for publication after submission.
4) PGX Scale-up: 80 days ago after completing three trial runs the 5X PGX scale-up was said "almost completed". Previously the 5X scale-up was expected to provide materials for potential partners. 52 business days until the 10X PGX scale-up is expected to be completed with Natex. Production from the 5X PGX scale-up could be approved by Health Canada for sale this year.
5) Immune Booster: "Protocol designed for a head-to-head study in animals for testing immune properties of PGX-YBG against a commercial formulation." November 29, 2023
6) Oat beta glucan chewy: Commercial launch expected in the second half of 2024.
7) NMOSD: In its Q1 report AEZS said it applied for a regulatory advice meeting in the near term. Studies ongoing.
8) Delayed Parathyroid Clearance Hormone: Planninng to meet with regulatory authorities and Initiate IND enabling studies for clinical trials.